Acceleron Pharma
We are seeking a talented and passionate individual who thrives in a dynamic, fast-paced, team-oriented, and collaborative environment to be part of our success. In this role, you will be a member of the Program Management team and be responsible for implementing, leading and coordinating the Project Management Office (PMO) area. Reporting to the Vice President – Program Management – Pulmonary, you will apply your expertise and understanding of drug development to establish a structure that standardizes the project/program-related processes and facilitates the sharing of resources, methodologies, tools, and techniques.
What will you be doing?
What are we looking for?
How will you grow with us?
You will be joining a growing and advancing company with an active pipeline and will help drive the pulmonary therapeutic area by collaborating with passionate team members. As a part of a dynamic team, you will have the ability to influence company`s portfolio, build ownership in your role and seek new opportunities for growth. If you are looking to be a part of an innovative and fast-paced environment, join our team!
*In compliance with federal law, all persons hired will be required to verify identity and eligibility to work in the United States and complete the required employment eligibility verification document form upon hire.
Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron’s leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body’s ability to regulate cellular growth and repair.Acceleron focuses its research, development, and commercialization efforts in pulmonary and hematologic diseases. In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension (PAH), having reported positive topline results of the PULSAR Phase 2 trial. The Company is currently planning multiple Phase 3 trials with the potential to support its long-term vision of establishing sotatercept as a backbone therapy for patients with PAH at all stages of the disease. Acceleron is also investigating the potential of its early-stage pulmonary candidate, ACE-1334, which it plans to advance into a Phase 1b/2 trial in systemic sclerosis-associated interstitial lung disease (SSc-ILD) next year. In hematology, REBLOZYL® (luspatercept-aamt) is the first and only erythroid maturation agent approved in the United States, Europe, and Canada for the treatment of anemia in certain blood disorders. REBLOZYL is part of a global collaboration partnership with Bristol Myers Squibb. The Companies co-promote REBLOZYL in the United States and are also developing luspatercept for the treatment of anemia in patient populations of myelodysplastic syndromes, beta-thalassemia, and myelofibrosis.For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.
You have been redirected to a Acceleron Pharma job page